Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.66 |
| ▸ | SELP | P16109 | 2/20 | 0.60 |
| ▸ | SELL | P14151 | 1/20 | 0.60 |
| ▸ | MAG | P20916 | 9/20 | 0.58 |
| ▸ | NANP | Q8TBE9 | 1/20 | 0.48 |
| ▸ | SELE | P16581 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29393136 | 1.00 | SIGLEC7 (0.66) | SIGLEC7SELPSELLMAGNANP | |
| SCHEMBL29454806 | 1.00 | SIGLEC7 (0.66) | SIGLEC7SELPSELLMAGNANP | |
| SCHEMBL30439275 | 0.96 | SIGLEC7 (0.62) | SIGLEC7SELPSELLMAGNANP | |
| SCHEMBL30439269 | 0.96 | SIGLEC7 (0.62) | SIGLEC7SELPSELLMAGNANP | |
| SCHEMBL29356627 | 0.95 | SELP (0.62) | SIGLEC7SELPSELLMAGNANP | |
| SCHEMBL29396615 | 0.95 | SELP (0.62) | SIGLEC7SELPSELLMAGNANP | |
| SCHEMBL17300130 | 0.95 | SELP (0.62) | SIGLEC7SELPSELLMAGNANP | |
| SCHEMBL31716489 | 0.93 | SIGLEC7 (0.70) | SIGLEC7SELPSELLMAGSELE | |
| SCHEMBL29615820 | 0.92 | SIGLEC7 (0.71) | SIGLEC7SELPSELLMAGSELE | |
| SCHEMBL29378134 | 0.92 | SIGLEC7 (0.76) | SIGLEC7SELPSELLMAGSELE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 316 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725503-A2 | CHIMERIC ANTIGEN RECEPTORS TARGETING CANCER | University Of Southern California (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260071235-A1 | METHODS FOR EXPANDING SARS-COV2-ANTIGEN-SPECIFIC T CELLS, COMPOSITIONS AND USES RELATED THERETO | ANGELES THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | claimed |
| EP-3516068-B1 | NON-RADIOACTIVE CYTOTOXICITY ASSAYS | UNIV SOUTHERN CALIFORNIA (US) | 2025-04-23 | — | — | EP | claimed |
| EP-4476354-A2 | FUSOGENIC RHABDOVIRUS GLYCOPROTEINS AND USES THEREOF | Interius Biotherapeutics, Inc. (US) | 2024-12-18 | — | — | EP | claimed |
| WO-2024220650-A2 | PURIFICATION OF VIRUSES AND VIRAL LIKE PARTICLES | INTERIUS BIOTHERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | claimed |
| EP-4448550-A2 | PSEUDOTYPED VIRAL PARTICLES, COMPOSITIONS COMPRISING THE SAME, AND USES THEREOF | Interius Biotherapeutics, Inc. (US) | 2024-10-23 | — | — | EP | claimed |
| EP-4305053-A1 | IMPROVING IMMUNE CELL FUNCTION | Kite Pharma, Inc. (US) | 2024-01-17 | — | — | EP | claimed |
| US-20230357717-A1 | CELL SECRETED MINIBODIES AND USES THEREOF | NOVARTIS AG (CH) | 2023-11-09 | — | — | US | claimed |
| US-20230304031-A1 | VECTORS AND METHODS FOR IN VIVO TRANSDUCTION | ABINTUS BIO INC (US) | 2023-09-28 | — | — | US | claimed |
| WO-2023154858-A2 | FUSOGENIC RHABDOVIRUS GLYCOPROTEINS AND USES THEREOF | INTERIUS BIOTHERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | claimed |
| EP-4149495-A1 | VECTORS AND METHODS FOR IN VIVO TRANSDUCTION | Abintus Bio, Inc. (US) | 2023-03-22 | — | — | EP | claimed |
| WO-2023023467-A1 | NUCLEIC ACID MOLECULES AND METHODS OF USING THE SAME | INTERIUS BIOTHERAPEUTICS, INC. (US) | 2023-02-23 | — | — | WO | claimed |
| US-11549099-B2 | Cell secreted minibodies and uses thereof | NOVARTIS AG (CH) | 2023-01-10 | — | — | US | claimed |
| EP-4097144-A1 | GENOME ENGINEERING THE HUMAN IMMUNOGLOBULIN LOCUS TO EXPRESS RECOMBINANT BINDING DOMAIN MOLECULES | University of Southern California (US) | 2022-12-07 | — | — | EP | claimed |
| WO-2022192439-A1 | IMPROVING IMMUNE CELL FUNCTION | KITE PHARMA, INC. (US) | 2022-09-15 | — | — | WO | claimed |
| US-20220289815-A1 | IMMUNE CELL FUNCTION | KITE PHARMA, INC. | 2022-09-15 | — | — | US | claimed |
| US-20220252606-A1 | NON-RADIOACTIVE CYTOTOXICITY ASSAYS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-08-11 | — | — | US | claimed |
| WO-2022155375-A2 | MHC-INDEPENDENT TCRs AND METHODS OF MAKING AND USING SAME | WASHINGTON UNIVERSITY (US) | 2022-07-21 | — | — | WO | claimed |
| US-20220135678-A1 | METHODS AND COMPOSITIONS TO IMPROVE THE SAFETY AND EFFICACY OF CELLULAR THERAPIES | NATIONAL INSTITUTES OF HEALTH | 2022-05-05 | — | — | US | claimed |
| US-20220090132-A1 | CAR T CELL METHODS AND CONSTRUCTS | ABINTUS BIO INC (US) | 2022-03-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260071235-A1 | METHODS FOR EXPANDING SARS-COV2-ANTIGEN-SPECIFIC T CELLS, COMPOSITIONS AND USES RELATED THERETO | CD4, HLA-DRB1, SARS1 | SIGLEC7 345/4885SELP 279/4885SELL 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.